{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:05:58Z","timestamp":1792317958040,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00198-019-04842-w","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T04:24:03Z","timestamp":1548303843000},"page":"939-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Pregnancy-associated osteoporosis: a UK case series and literature review"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-4873","authenticated-orcid":false,"given":"S.A.","family":"Hardcastle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Yahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"4842_CR1","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/EJE-14-0424","volume":"172","author":"L Sanz-Salvador","year":"2015","unstructured":"Sanz-Salvador L, Garcia-Perez MA, Tarin JJ, Cano A (2015) Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture. Eur J Endocrinol 172:R53\u2013R65","journal-title":"Eur J Endocrinol"},{"key":"4842_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/MED.0000000000000102","volume":"21","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS (2014) Osteoporosis presenting in pregnancy, puerperium, and lactation. Curr Opin Endocrinol Diabetes Obes 21:468\u2013475","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"4842_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.bone.2003.11.005","volume":"34","author":"D Pearson","year":"2004","unstructured":"Pearson D, Kaur M, San P, Lawson N, Baker P, Hosking D (2004) Recovery of pregnancy mediated bone loss during lactation. Bone 34:570\u2013578","journal-title":"Bone"},{"key":"4842_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s00198-011-1654-6","volume":"23","author":"UK Moller","year":"2012","unstructured":"Moller UK, Vieth Streym S, Mosekilde L, Rejnmark L (2012) Changes in bone mineral density and body composition during pregnancy and postpartum. A controlled cohort study. Osteoporos Int 23:1213\u20131223","journal-title":"Osteoporos Int"},{"key":"4842_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1152\/physrev.00027.2015","volume":"96","author":"CS Kovacs","year":"2016","unstructured":"Kovacs CS (2016) Maternal mineral and bone metabolism during pregnancy, lactation, and post-weaning recovery. Physiol Rev 96:449\u2013547","journal-title":"Physiol Rev"},{"key":"4842_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/cen.13557","volume":"88","author":"N Hong","year":"2018","unstructured":"Hong N, Kim JE, Lee SJ, Kim SH, Rhee Y (2018) Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis. Clin Endocrinol 88:652\u2013658","journal-title":"Clin Endocrinol"},{"key":"4842_CR7","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1007\/s00198-015-3149-3","volume":"26","author":"CS Kovacs","year":"2015","unstructured":"Kovacs CS, Ralston SH (2015) Presentation and management of osteoporosis presenting in association with pregnancy or lactation. Osteoporos Int 26:2223\u20132241","journal-title":"Osteoporos Int"},{"key":"4842_CR8","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00198-016-3897-8","volume":"28","author":"P Hadji","year":"2017","unstructured":"Hadji P, Boekhoff J, Hahn M, Hellmeyer L, Hars O, Kyvernitakis I (2017) Pregnancy-associated osteoporosis: a case-control study. Osteoporos Int 28:1393\u20131399","journal-title":"Osteoporos Int"},{"key":"4842_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00198-017-4239-1","volume":"29","author":"I Kyvernitakis","year":"2018","unstructured":"Kyvernitakis I, Reuter TC, Hellmeyer L, Hars O, Hadji P (2018) Subsequent fracture risk of women with pregnancy and lactation-associated osteoporosis after a median of 6 years of follow-up. Osteoporos Int 29:135\u2013142","journal-title":"Osteoporos Int"},{"key":"4842_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1007\/s00198-006-0112-3","volume":"17","author":"SM O'Sullivan","year":"2006","unstructured":"O'Sullivan SM, Grey AB, Singh R, Reid IR (2006) Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int 17:1008\u20131012","journal-title":"Osteoporos Int"},{"key":"4842_CR11","volume-title":"Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"J Compston","year":"2013","unstructured":"Compston J (2013) Skeletal effects of drugs. In: Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th edn. John Wiley & Sons, Hoboken","edition":"8"},{"key":"4842_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00198-014-2852-9","volume":"26","author":"D Ozdemir","year":"2015","unstructured":"Ozdemir D, Tam AA, Dirikoc A, Ersoy R, Cakir B (2015) Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. Osteoporos Int 26:415\u2013418","journal-title":"Osteoporos Int"},{"key":"4842_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/bjs.4809","volume":"92","author":"AE Handschin","year":"2005","unstructured":"Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O (2005) Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 92:177\u2013183","journal-title":"Br J Surg"},{"key":"4842_CR14","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1210\/jc.2013-3238","volume":"99","author":"N Campos-Obando","year":"2014","unstructured":"Campos-Obando N, Oei L, Hoefsloot LH, Kiewiet RM, Klaver CCW, Simon MEH, Zillikens MC (2014) Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause. J Clin Endocrinol Metab 99:1107\u20131111","journal-title":"J Clin Endocrinol Metab"},{"key":"4842_CR15","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/jbmr.2095","volume":"29","author":"FJ Cook","year":"2014","unstructured":"Cook FJ, Mumm S, Whyte MP, Wenkert D (2014) Pregnancy-associated osteoporosis with a heterozygous deactivating LDL receptor-related protein 5 (LRP5) mutation and a homozygous methylenetetrahydrofolate reductase (MTHFR) polymorphism. J Bone Miner Res 29:922\u2013928","journal-title":"J Bone Miner Res"},{"key":"4842_CR16","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00198-018-4460-6","volume":"29","author":"KE Naylor","year":"2018","unstructured":"Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R (2018) Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int 29:1407\u20131417","journal-title":"Osteoporos Int"},{"key":"4842_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.14310\/horm.2002.1319","volume":"10","author":"IP Stathopoulos","year":"2011","unstructured":"Stathopoulos IP, Liakou CG, Katsalira A, Trovas G, Lyritis G, Papaioannou N, Tournis S (2011) The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens) 10:280\u2013291","journal-title":"Hormones (Athens)"},{"key":"4842_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.reprotox.2006.05.009","volume":"22","author":"A Ornoy","year":"2006","unstructured":"Ornoy A, Wajnberg R, Diav-Citrin O (2006) The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22:578\u2013579","journal-title":"Reprod Toxicol"},{"key":"4842_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bone.2008.11.001","volume":"44","author":"S Levy","year":"2009","unstructured":"Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, Moretti M, Koren G, Ito S (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44:428\u2013430","journal-title":"Bone"},{"key":"4842_CR20","first-page":"139","volume":"11","author":"G Zarattini","year":"2014","unstructured":"Zarattini G, Buffoli P, Isabelli G, Marchese M (2014) Pregnancy-associated osteoporosis with seven vertebral compression fractures, a case treated with strontium ranelate. Clin Cases Miner Bone Metab 11:139\u2013141","journal-title":"Clin Cases Miner Bone Metab"},{"key":"4842_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.14310\/horm.2002.1383","volume":"11","author":"K Lampropoulou-Adamidou","year":"2012","unstructured":"Lampropoulou-Adamidou K, Trovas G, Stathopoulos IP, Papaioannou NA (2012) Case report: Teriparatide treatment in a case of severe pregnancy -and lactation- associated osteoporosis. Hormones (Athens) 11:495\u2013500","journal-title":"Hormones (Athens)"},{"key":"4842_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3109\/09513591003649831","volume":"26","author":"L Hellmeyer","year":"2010","unstructured":"Hellmeyer L, Boekhoff J, Hadji P (2010) Treatment with teriparatide in a patient with pregnancy-associated osteoporosis. Gynecol Endocrinol 26:725\u2013728","journal-title":"Gynecol Endocrinol"},{"key":"4842_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s00774-011-0334-0","volume":"30","author":"EY Choe","year":"2012","unstructured":"Choe EY, Song JE, Park KH, Seok H, Lee EJ, Lim SK, Rhee Y (2012) Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab 30:596\u2013601","journal-title":"J Bone Miner Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04842-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-04842-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04842-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T19:16:52Z","timestamp":1579720612000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-04842-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4842"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-04842-w","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"16 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SH has received conference fee support from Lilly UK. FY has received funding for attending congresses and speaker fees from Pfizer, Novartis and Abbvie and grant\/advisory board for Novartis. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}